The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

PARP inhibitors are considered promising anti-cancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Velipari...

Descripción completa

Detalles Bibliográficos
Autores principales: Arun, Banu, Akar, Ugur, Gutierrez-Barrera, Angelica M., Hortobagyi, Gabriel N., Ozpolat, Bulent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904111/
https://www.ncbi.nlm.nih.gov/pubmed/25975349
http://dx.doi.org/10.3892/ijo.2015.3003